Abstract: The present invention refers to controlled release granular compositions of mesalazine and their use in the treatment of inflammatory pathologies of the intestinal tract. The aforesaid granular compositions comprise: a) a central core comprising an inert substrate; b) an intermediate layer comprising mesalazine and one or more physiologically acceptable excipients; c) a gastro-resistant coating. The present invention then refers to a process for obtaining the aforesaid granular compositions.

Abstract: Improved oil-in-water emulsions are provided and a method for their manufacture. In particular, the emulsions comprise a means to control delivery of oil-soluble or water-soluble actives in a core comprising a liquid oil or gel oil continuous phase, which actives can be delivered with improved deposition to surfaces such as, in particular, the skin, gastro-intestinal tract and that defined by the oral cavity. The emulsions are also noted for their improved stability.

Abstract: The present invention relates to oligomeric or polymeric saccharide derivatives comprising glucosamine moieties, e.g. derivatives of oligomeric or polymeric glucosamines such as chitosan oligomers or polymers, in which one or more amine groups are substituted by anchoring groups that chemisorb to the surface of a nanoparticle or form an interdigitated bilayer with a surfactant layer surrounding the nanoparticle. The invention also relates to functionalized nanoparticles comprising such derivatives, a method for forming the functionalized particles and to uses thereof as molecular imaging agents, biosensing agents or drug delivery agents, or in the preparation of such agents.

Abstract: A compound for detecting an analyte using Surface Enhanced Raman Spectroscopy (SERS) and a method of forming the compound is provided. The compound has Formula I: wherein W is selected from the group consisting of an optionally substituted aryl group and an optionally substituted heteroaryl group; each Y independently is NR1R2, wherein R1 and R2 are independently selected from the group consisting of H and C1-C6 alkyl, or R1 and R2 combine to form together with the nitrogen to which they are attached a heterocyclic group with 4 to 5 carbon atoms, is used to denote a single or a double bond, and Z is NH, NH2, NH—(C?O)—(CH2)n—SH, wherein n=1 to 10, or or a tautomer or stereoisomer thereof, or a salt thereof. A method and device for detecting an analyte using Surface Enhanced Raman Spectroscopy (SERS) is also provided.

Abstract: A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating. Each Timed Pulsatile Release (TPR) bead population exhibits pre-determined lag-time followed by differing release characteristics. The composition and thickness of the barrier coating, composition and thickness of the lag-time coating, ratio of IR beads to one or more TPR bead populations and total dose may be varied depending on the alkalinity, pH-dependent solubility and elimination half-life of the active ingredients to achieve target PK profiles (suitable for a once or twice daily dosing regimen) in patients in need of such medications.

Abstract: Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal.

Abstract: The invention relates to Polysaccharide-coated GoldMag particles (DPGPs) and the method of its synthesis, which characterized GoldMag particles as a core and natural or synthetic biodegradable polysaccharide such as dextran, cyclodextrin and derivatives as shell. DPGPs are synthesized by mixing Polysaccharide-coated GoldMag particles (DPGPs) with drug through physical bond. The preparation of the drug-loaded composite particles include: preparing the polysaccharide-coated GoldMag particles and then loading the drug on the polysaccharide-coated GoldMag particles. The drug-loading process is carried out through directly mixing the polysaccharide-coated GoldMag particles with the drug solution by the shaker. That means the polysaccharide-coated GoldMag particles load the drug through affinity adsorption.

Abstract: The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates and oral and nasal dosing systems including same are also contemplated. The process produces agglomerates which are rugged but which will produce an acceptable fine particle fraction during dosing.

Abstract: Embodiments of a method for nucleic acid-mediated control of a nanoparticle shape are disclosed. In some embodiments, one or more nucleic acid oligomers are adsorbed to a metal nanoseed, and additional metal is deposited onto the nanoseed to produce a shaped nanoparticle. In certain embodiments, the nanoseed is gold and the oligomers are 5-100 nucleotides in length. The nanoparticle shape is determined at least in part by the nucleic acid sequence of the oligomer(s). Shaped nanoparticles produced by embodiments of the method include nanoflowers, nanospheres, nanostars, and nanoplates. Embodiments for using the shaped nanoparticles also are disclosed.

Abstract: A bone graft or biocomposite for treating osseous defects and neogenesis of bone which is a composite of a biodegradable polymer and granules of beta-tricalciumphosphate, further comprising as active ingredient and embedded in the biodegradable polymer a physiologically effective amount of underglycosylated recombinant human BSP as a muti-dental clathrate with a basic organic compound which simulataneously is active as a plasticizer for the biodegradable polymer. The biocomposite is moldable and shapeable, hardens rapidly in situ when placed by surgery or prosthetic dentistry and which furthers osseous repair and the healing of damage or diseased tissues and lesions.

Abstract: This present disclosure relates to pharmaceutical compositions for treating tumors using a polymeric micelle encapsulating an anti-tumor drug. The polymeric micelle comprises block copolymers comprising at least one hydrophilic block, at least one hydrophobic block, and at least one zwitterion. The present disclosure also relates to methods of enhancing the solubility of such drugs, methods of increasing the blood circulating time of such drugs, and methods of delivering such drugs to one or more solid tumors.

Abstract: The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells using biocompatible bioabsorbable nanospheres. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.

Abstract: The invention relates to a gastric resistant pharmaceutical or nutraceutical composition, comprising a core, comprising a pharmaceutical or nutraceutical active ingredient and a gastric resistant coating layer onto the core, wherein the release of the pharmaceutical or nutraceutical active ingredient is not more than 15% under in-vitro conditions at pH 1.

Abstract: Microcapsules including a capsule shell encapsulating a suspension of a therapeutically effective amount of liver cells in physical contact with a liver cell stimulating amount of erythropoietin.

Abstract: The present invention relates to the field of drug delivery nanosystems. More precisely, the present invention concerns a copolymer with advantageous properties for the outer coating of various nanoparticles. Said copolymer comprises at least three types of monomers with stealthy, coupling and therapeutic properties respectively, as well as an optional fourth type of monomers with targeting properties. The present invention also relates to core-shell or hollow shell nanoparticles coated by an external layer of the copolymer according to the invention. Several types of core-shell nanoparticles are envisaged. The invention also concerns methods for preparing said nanoparticles, as well as pharmaceutical compositions or medicaments comprising them.

Abstract: Disclosed are drug delivery systems and methods for extravascular administration of drug, vaccine, and/or diagnostic agents, for use in research and medical applications.

Abstract: Microcapsules for delivery of a liquid onto a surface such as a hard surface or a textile, such as mattress ticking, are disclosed. The microcapsules have a shell with an outer face and an inner face, the inner face encapsulating the liquid, and the liquid contains a microorganism such as a beneficial microorganism in a dormant state. The outer face of the microcapsules may comprise reactive functional groups whereby the outer face is chemically bondable, for instance covalently bondable to said surface. The microcapsules provide a beneficial microflora on said surface by rupture of the capsules deposited onto said surface to release the microorganism onto said surface. This may reduce or obviate the need for chemical antimicrobial agents to clean said surface. For surfaces which are fabrics or textiles, rupture and release may occur during use of the fabric or textile.

Abstract: The present invention is directed to anti-hypertensive compositions comprising a nanoparticulate temocapril, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate temocapril particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of hypertension and related diseases.

Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.

Abstract: An injectable smart gel and a method for fabricating the same are disclosed. A basic structural stabilizer/polymeric electrolyte and a diluting solution are added to a modified chitosan to regulate the chitosan solution to have a pH value closing to that of the human body and form a flowable chitosan sol. The flowable chitosan sols formed thereby are respectively converted into inflowable chitosan gels via increasing the temperature thereof to the human body temperature, and via adding calcium ion or regulating the chitosan sol into an acidic solution. The injectable smart gel fabricated thereby is injectable and able to function as a carrier of magnetism-sensitive medicine-containing nanocapsules. The medicine can be released to the injectable smart gel with an external non-contact force, such as a magnetic field, an electric field or an ultrasonic wave, for long-acting and multi-stage medicine delivery. The present invention is very useful in biomedical engineering.

Abstract: Sunscreen compositions containing a discontinuous oil phase dispersed in a continuous water phase, at least 10% by weight of an organic UV-filter, a water-insoluble, C2-C8, liquid silicone, a branched fatty acid ester of a polyprotic carboxylic acid; and at least 2% by weight of a mineral particulate having a starch coating applied to the surface thereof.

Abstract: Stabilized substituted benzimidazole modified release pharmaceutical formulations with at least two drug-containing fractions, wherein the release from a first fraction precedes the release from a second fraction, pharmaceutical excipients, processes for preparing the stable formulations, packaging therefor, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.

Abstract: This invention relates to the field of chemical pharmaceutical industry, namely, to pharmaceutical formulations for preparation of prolonged release tablets, in particular, tablets for sublingual application, and to methods of preparation of such formulations. Pharmaceutical formulation comprises 96.0 to 99.8% wt. of the pharmaceutical drug microcapsules, 0.1 to 1% wt. of lubricant, and 0.1 to 3% wt. of water, each microcapsule comprising 96.0 to 99.2% wt. of the pharmaceutical drug and 0.8 to 4% wt. of film-forming substance. Dispersant is also introduced into formulation in the amount of 0.1 to 10% wt. of the total mixture obtained. Method of preparation of the pharmaceutical formulation comprises preparation of microcapsules by deposition of coating of film-forming substance on non-agglomerated particles of pharmaceutical drug, and addition of lubricant and dispersant.

Abstract: A composition is provided which comprises an acidic component, generally fulvic acid, having a molecular weight not exceeding 20,000 Daltons and a low content of the elements aluminum, mercury, cadmium, chromium and lead. The acidic component is preferably carbohydrate derived and preferably using a wet oxidation process.

Abstract: Described herein are compositions comprising one or more embolics attached to an inert, dissolvable matrix as well as kits comprising these novel embolic formulations. Also described are methods of making and using these embolic formulations.

Abstract: A drug composition comprising a coated bead is used in the manufacture of immediate release and/or controlled release drug compositions. In a specific embodiment, the bead includes an inert core of a water-soluble or water-swellable material, which has been coated with a seal layer formed from a non-polymeric hydrophobic material. The immediate and/or controlled release beads may be used to form tablets or capsules. A method of making the beads by sequential deposition of multiple layers on the inert cores is also described.

Abstract: This invention generally relates to methods for treating or preventing the symptoms of non-alcoholic fatty liver disease, methods for reducing excessive fat from the liver, methods of improving glycemic control, and methods for treating or preventing liver dysfunction, that comprise administering a therapeutically effective amount of Adenovirus 36 E4orf1 protein or functional variant thereof.

Abstract: A formulation for use in an inhaler device comprises carrier particles having a diameter of at least 50 ?m and a mass median diameter of at least 175 ?m; fine particles of an excipient material having a mass median aerodynamic diameter of not more than 20 ?m; and active particles. The formulation has excellent flowability even at relatively high contents of fine particles.

Abstract: The present invention relates to a new type of functionalized nanoparticles for drug delivery, comprising a type of polymer nanoparticles, a polymer stabilizer coating, and a drug, wherein said polymer stabilizer coating is coated on the surface of said type of polymer nanoparticles, and said drug is conjugated to said polymer stabilizer coating. The present invention also relates to a method for preparing the nanoparticles; and provides a method for treating an ischemic or degenerative disease, comprising administrating an effective amount of the type of functionalized nanoparticles to a subject.

Abstract: Nutritional compositions delivered in vivo in a time controlled manner sustainable over long periods of time, provide enhancing athletic performance, increased hand/eye coordination and concentration on the task at hand.

Abstract: The present invention relates to synthesis of oligonucleotide mediated gold core- silver shell nanoparticles and testing their SERS performance. A Raman reporter molecule and twelve-base long oligonucleotide are simultaneously attached on gold nanoparticles and a silver layer is deposited on the modified gold nanoparticles. The SERS performance of gold core- silver shell nanoparticles (CSNPs) is much greater than the CSNPs prepared without oligonucleotides and the same size non-modified gold nanoparticles after silver staining.

Abstract: A gold-coated iron oxide nanoparticle, method of making thereof, and method of using thereof is disclosed. The nanoparticle is substantially toxin free (making it clinically applicable), easily functionalized, and can serve as a contrast agent for a number of imaging techniques, including imaging a subject in at least two distinct imaging modes. Further, the nanoparticle is well-suited for therapeutic uses.

Abstract: The present invention relates to crosslinked dextran magnetic composite microparticles and a preparation process and a using method thereof. The composite microparticles comprise magnetic nanoparticles and dextran with crosslinked structure, wherein the magnetic nanoparticles are dispersed in the dextran with crosslinked structure. The process for preparing the composite microparticles comprises: preparing a dextran solution; synthesizing dextran magnetic composite microparticles; and synthesizing the crosslinked dextran magnetic composite microparticles. The using method of composite microparticles comprises: preparing crosslinked dextran magnetic composite microparticles loaded with anti-cancer drug; and adding a sustained-releasing solution thereto.

Abstract: Particles comprising a core based on at least one biodegradable organosoluble polymer. At least a part of the surface of the particles is coated with at least one hyaluronan or a derivative thereof, the hyaluronan being a water-soluble, amphiphilic hyaluronan of which the carboxylic functions are in part transformed to form hydrophobic groups.

Abstract: An immunogenic composition includes as an effective ingredient an antigen-adjuvant microparticle complex containing an antigen encapsulated in an adjuvant microparticle composed of an amphiphilic polymer(s) whose hydrophobic segment is a poly(hydroxy acid), or a particle composed of the antigen-adjuvant microparticle complex associated together, can induce a high immune response against the antigen even with a small amount of the antigen and a small number of doses, so that the immunogenic composition is useful as a vaccine effective for therapy and prophylaxis of infectious diseases, cancer and the like.

Abstract: The disclosure relates to imaging agents and drug delivery systems.

Abstract: The present invention relates to a granule of gamma-hydroxybutyric acid or of one of its pharmaceutically acceptable salts, characterized in that it comprises a solid core on which the gamma-hydroxybutyric acid or one of its salts is supported.

Abstract: The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.

Abstract: The present invention relates to a method for preparing a granulate of at least two active principles, including a step of applying said active principles to a solid particulate medium by dusting, said active principles not being plant extracts.

Abstract: A method of diagnosing and treating a human glioblastoma multiforme (GBM) brain tumor in a subject is disclosed. The method includes administering to the subject, an effective amount of composition having a peptide 12-20 amino acid residues in length and selected for its ability to bind preferentially to a subtype of human GBM cells identified as brain tumor initiating cells (BTICs) or highly invasive glioma cells (HIGCs).

Abstract: Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation.

Abstract: This invention provides coral-based scaffolds for cartilage repair, and instruments for insertion and utilization of same within a site of cartilage repair.

Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially insoluble or sparingly soluble in water, in combination with a bioadhesion and/or mucoadhesion promoting agent adhered to the surfaces of said carrier particles. The composition is primarily intended for sublingual or intranasal administration. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.

Abstract: The present invention provides pharmaceutically acceptable compositions for once-daily dosing comprising a piperazine derivative of H1-receptor antagonists, or its salt, and/or solvate and methods of making and using the compositions in the treatment of treating vertigo and other diseases. The present invention also provides once-a-day dosage forms as orally disintegrating tablets comprising compositions of the present invention.

Abstract: A controlled release pharmaceutical dosage form for controlled release of an active ingredient, includes an active ingredient coated by a polymeric mixture of: at least a water insoluble polymer; and at least an indigestible water-soluble oligosaccharide. The use and method of making the same are also described.

Abstract: Libraries of nanoparticles comprising therapeutic agents and/or imaging agents are disclosed, as well as methods of making, customizing, and using such libraries of nanoparticles.

Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.

Abstract: Novel calcium phosphate core particles, methods of making them, and methods of using them as vaccine adjuvants, as cores, as carriers of biologically active material, and as controlled release matrices for biologically active material are disclosed. The core particles may have a surface modifying agent and/or biologically active material, such as antigenic material or natural immunoenhancing factor, polynucleotide material, or therapeutic proteins or peptides, partially coating the particle or impregnated therein.

Abstract: The present invention encompasses a composition capable of delivering and expressing a nucleic acid encoding UDP-Glucuronosyltransferases, p53 or a combination thereof into a cell, and methods for treating tumors.

Abstract: A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.